Trump Admin Secures Regeneron MFN Deal to Cut Drug Costs and Boost U.S. Manufacturing

Trump announced Regeneron’s MFN pricing deal to align U.S. prices with the lowest prices in developed nations, giving Medicaid access to MFN prices on new Regeneron medicines and cutting Praluent’s price from $537 to $225 for direct TrumpRx purchasers; all new Regeneron drugs will carry MFN pricing in the U.S. The pact also includes Otarmeni, a rare-gene therapy, provided at no cost to American families via the FDA's Priority Voucher program. Regeneron pledges $27 billion to U.S. R&D and onshore manufacturing by 2029, part of a broader push that has attracted about $448 billion in domestic pharmaceutical investments in 15 months. The administration has now secured MFN deals with 17 major manufacturers, covering roughly 86% of the branded drug market.